Navigation Links
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) earlier this quarter.

"This is a significant milestone for Pharmasset. PSI-7851 is a wholly owned, second generation nucleotide analog that was discovered by Pharmasset scientists" stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We continue to see nucleos(t)ide inhibitors as having the potential to be the cornerstone of future HCV treatment, given their higher barrier to resistance and antiviral activity across multiple HCV genotypes, characteristics that set them apart from other HCV drug classes. We look forward to reporting the first antiviral data with PSI-7851 in the second half of 2009."

About PSI-7851

PSI-7851 is a uridine nucleoside analog currently in developed for the treatment of chronic HCV infection. PSI-7851 has demonstrated in vitro anti-HCV activity with EC(50) values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than the active metabolite of Pharmasset's first generation nucleoside polymerase inhibitor, R7128. In vitro studies of PSI-7851 have not shown evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Like R7128, PSI-7851 has demonstrated in vitro activity against all of the most common HCV genotypes.

About Pharmasset'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2008 Financial Results
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
4. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
5. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
8. Pharmasset Receives Notice of Allowance
9. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Kindred Hospital Houston Northwest, ... the opening of its new outpatient wound healing ... to people with chronic, hard to heal wounds. ... lead to amputation, lower leg wounds related to ... closure, and traumatic injury wounds which are complex ...
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... 2011 In conjunction with its first quarter 2011 earnings ... 4, 2011), Covance Inc. (NYSE: CVD ) is ... conference call that will be broadcast live over the Internet ... Covance First Quarter 2011 Earnings Webcast and Slide PresentationWhen: , ...
... Aribex®, Inc., the worldwide leader in handheld x-ray technologies, has ... premier Practice Management System for dental clinics, to contribute up ... the earthquake and tsunami in Japan. The first two kits ... of the most damaged areas. Each kit will ...
Cached Medicine Technology:Aribex and IDENS Donate 15 Victim I.D. Kits for Japan 2
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... North American water storage systems market is estimated to grow ... at a CAGR of 21.0%, from 2013 to 2018. The ... in North America. The U.S. is experiencing high growth on ... and collection, and the increased spending on modernization and upgradation ... rate in Canada, and is rising at a rapid pace ...
(Date:7/13/2014)... 2014 According to a new ... Market by Component (processor, GPU, DSP, connectivity), Technology ... and Geography - Forecast and Analysis to 2014-2020", ... & Computing Market is expected to reach $61.70 ... 20.75% from 2014 to 2020. , Browse 71 ...
(Date:7/13/2014)... Seattle, WA (PRWEB) July 13, 2014 ... a longer recovery period from concussions, according to research ... Medicine’s ( AOSSM ) Annual Meeting. The research marks ... to concussion based on the known physical events that ... that patients with a long allele in the (GT)n ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fadhits.com is ... sexy prom dresses are extremely beautiful. Recently, the company ... dresses for 2014. What’s more, all these outfits ... percent off). , Additionally, the supplier is now ... with elegant Quinceanera dresses, it has many other designs ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2
... University of Texas Medical Branch at Galveston (UTMB) have found ... cause the “mad cow disease” in people. According to their ... that are there in the blood causing the disease.// ... of Nature Medicine. The findings from the study are expected ...
... syndrome is an endocrine disorder characterized by nervous ... headache and pelvic congestion. ,For the first ... progestin and dosing regimen has been found effective ... the most severe form of premenstrual syndrome. ...
... Ministry of Health is in search of a new cheaper ... Government has reported 200 deaths and 700 patients with infection. ... due to the endemic infection of Encephalitis in Uttar Pradesh. ... 67 patients were admitted in the Government College Hospital in ...
... Dame University have developed unusual antibiotics that have the ... research findings were presented at the 230th national meeting ... society. // ,The new antibiotics are synthetic ... penicillin. They appear to kill bacteria by masquerading as ...
... form of cancer and nearly one out of every three cancers ... the more alarming is that 73% of people with fair skin ... they still get sunburnt despite almost two thirds worrying it could ... is the cause of nearly all types of skin cancer occurring ...
... Chitosan, a dietary supplement used in treating obesity and ... against weight loss. The researcher that had systematically reviewed ... findings in the latest issue of The Cochrane Library.// ... randomized controlled trials that included 1,131 overweight or obese ...
Cached Medicine News:Health News:They Call It PMS Because Mad Cow Disease Was Already Taken 2Health News:Atypical Antibiotics For Super Bugs 2
... therapeutic benefits of controlled compression to minimize ... pain. The cuff is anatomically designed to ... The Ankle Cryo/Cuff is one-size for adults ... size.,All Cryo/Cuffs can be ordered as a ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
Medicine Products: